Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone.

Patients with superficial transitional cell carcinoma of the bladder were entered in a randomized clinical trial to compare the efficacies of transurethral resection alone or followed by bladder instillation of doxorubicin hydrochloride or ethoglucid (Epodyl) for 1 year. Results showed that adjuvant chemotherapy with the selected drugs prolonged the mean interval between recurrences. Mild systemic toxicity and chemical cystitis were observed in 3 and 3 per cent, respectively, of the patients given ethoglucid, and in 5 and 4 per cent, respectively, of those taking doxorubicin.

[1]  L. Denis.  ANAPHYLACTIC REACTIONS TO REPEATED INTRAVESICAL INSTILLATION WITH CISPLATIN , 1983, The Lancet.

[2]  H. Grossman,et al.  Current therapy of bladder carcinoma. , 1979, The Journal of urology.

[3]  D. Byar,et al.  Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. , 1977, Urology.

[4]  S. Crooke,et al.  Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report. , 1980, Cancer treatment reports.

[5]  S. Murata,et al.  Mitomycin C bladder instillation therapy for bladder tumors. , 1975, The Journal of urology.

[6]  H. M. Weyrauch,et al.  Dissemination of bladder neoplasms by endoscopic electroresection. , 1962, Transactions of the American Association of Genito-Urinary Surgeons.

[7]  O. Dalesio,et al.  Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. , 1983, The Journal of urology.

[8]  P. Hochstein,et al.  POTENTIAL VARIANTS OF PHENYLKETONURIA , 1975, The Lancet.

[9]  M. Soloway,et al.  Serial multiple-site biopsies in patients with bladder cancer. , 1978, The Journal of urology.

[10]  M. Buyse,et al.  Cancer Clinical Trials: Methods and Practice. , 1985 .

[11]  G. Jakse,et al.  Intracavitary doxorubicin hydrochloride therapy for carcinoma in situ of the bladder. , 1981, The Journal of urology.

[12]  G. Farrow,et al.  Benign papilloma or papillary carcinoma of the bladder? , 1973, The Journal of urology.

[13]  O. Dalesio,et al.  Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone. , 1982, European urology.

[14]  M. Soloway,et al.  Susceptibility of urothelium to neoplastic cellular implantation. , 1975, Urology.

[15]  J. Fitzpatrick,et al.  Long-term follow-up in patients with superficial bladder tumours treated with intravesical Epodyl. , 1979, British journal of urology.

[16]  K. Kurth,et al.  Studies on the intravesical action of topically administered G3H-doxorubicin hydrochloride in men: plasma uptake and tumor penetration. , 1980, The Journal of urology.

[17]  H. Huland,et al.  Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients. , 1983, European urology.

[18]  P. Nieh,et al.  The effect of intravesical thio-tepa on normal and tumor urothelium. , 1978, The Journal of urology.

[19]  J. Pontes,et al.  Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder. , 1977, The Journal of urology.

[20]  F. Longo,et al.  Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors. , 1969, The Journal of urology.

[21]  M. Robinson,et al.  Intravesical epodyl in the management of bladder tumors: combined experience of the Yorkshire Urological Cancer Research Group. , 1977, The Journal of urology.